These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 10418898)
1. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Moore A; McCarthy L; Mills KH Vaccine; 1999 Jun; 17(20-21):2517-27. PubMed ID: 10418898 [TBL] [Abstract][Full Text] [Related]
2. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857 [TBL] [Abstract][Full Text] [Related]
3. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265 [TBL] [Abstract][Full Text] [Related]
4. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Ahmed FK; Clark BE; Burton DR; Pantophlet R Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis. Yang QB; Martin M; Michalek SM; Katz J Infect Immun; 2002 Jul; 70(7):3557-65. PubMed ID: 12065496 [TBL] [Abstract][Full Text] [Related]
6. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice. Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091 [TBL] [Abstract][Full Text] [Related]
7. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332 [TBL] [Abstract][Full Text] [Related]
8. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264 [TBL] [Abstract][Full Text] [Related]
10. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296 [TBL] [Abstract][Full Text] [Related]
11. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. Mazumder S; Maji M; Ali N PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029 [TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Sasaki S; Tsuji T; Hamajima K; Fukushima J; Ishii N; Kaneko T; Xin KQ; Mohri H; Aoki I; Okubo T; Nishioka K; Okuda K Infect Immun; 1997 Sep; 65(9):3520-8. PubMed ID: 9284115 [TBL] [Abstract][Full Text] [Related]
13. Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory [correction of imunostimulatory] oligonucleotides--relevance to AIDS vaccines in developing countries. Ayash-Rashkovsky M; Weisman Z; Diveley J; Moss RB; Bentwich Z; Borkow G Vaccine; 2002 Jun; 20(21-22):2684-92. PubMed ID: 12034094 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Qiao M; Murata K; Davis AR; Jeong SH; Liang TJ Hepatology; 2003 Jan; 37(1):52-9. PubMed ID: 12500188 [TBL] [Abstract][Full Text] [Related]
15. STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity. Varikuti S; Oghumu S; Natarajan G; Kimble J; Sperling RH; Moretti E; Kaplan MH; Satoskar AR Int Immunol; 2016 Nov; 28(11):565-570. PubMed ID: 27578456 [TBL] [Abstract][Full Text] [Related]
16. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Ryan M; McCarthy L; Rappuoli R; Mahon BP; Mills KH Int Immunol; 1998 May; 10(5):651-62. PubMed ID: 9645613 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons . Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282 [TBL] [Abstract][Full Text] [Related]
18. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Wheeler AW; Marshall JS; Ulrich JT Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351 [TBL] [Abstract][Full Text] [Related]
19. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A. Zhang P; Lewis JP; Michalek SM; Katz J Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367 [TBL] [Abstract][Full Text] [Related]
20. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; Beddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J Vaccine; 2000 Jan; 18(13):1166-77. PubMed ID: 10649617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]